Table 2.
Disease activity, course of pregnancy and nursing period.
| Patient A | Patient B | ||
|---|---|---|---|
| Pregnancies | |||
| Prior pregnancies | None | One pregnancy | |
| 1st pregnancy | 2nd pregnancy | 3rd pregnancy | |
| CS activity at conception | complete remission | complete remission | complete remission |
| age at delivery (y) | 32 | 35 | 33 |
| pregnancy duration (gw) | 38 | 40 | 41 + 3 |
| Mode of delivery | spontaneous vaginal in labor | spontaneous vaginal in labor | spontaneous vaginal in labor |
| Child’s condition at birth | healthy | healthy | healthy |
| APGAR score | 10/10 | 9/10 | 10 / 10 |
| Umbilical cord pH | 7.25 | 7.29 | 7.22 |
| Neonatal weight (g) | 3270 | 3740 | 399 |
| Neonatal length (cm) | 54 | 54 | 57 |
| Head circumference (cm) | 35 | 33.5 | 36.5 |
| Intrauterine development | percentile-appropriate | percentile-appropriate | percentile-appropriate |
| Postpartum complications | None | None | none |
| Treatment during pregnancy and nursing period | |||
| 1st trimester | CZP, PRED 5mg | CZP, PRED 4mg | CZP |
| 2nd trimester | CZP, PRED 4mg | CZP, PRED 4mg | CZP |
| 3rd trimester | CZP, PRED 4mg | CZP, PRED 4mg | CZP |
| Breast feeding | no breast feeding | no breast feeding | yes (CZP continued) |
| Follow up after birth (m) | 59 | 29 | 28 |
| Total duration of CZP treatment (months) | 74 | 41 | |
APGAR, Appearance, Pulse, Grimace, Activity, Respiration Score; cm, centimeters; CS, Cogan’s syndrome; CZP, certolizumab pegol; g, gram; gw, gestational weeks; m, months; PRED, prednisone; y, years.